| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Mylan Laboratories has a current Overall Rating of B (Positive). | 7 |
$25 |
| 25-Nov-2009 | New Constructs, LLC |
N/A
| MYL: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 25-Nov-2009 | Pechala's Reports | Lubomir Pechala | MYLAN INC (MYL=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 24-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (MYL). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (MYL). | 5 |
$18 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| S&P 500 Composite Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$40 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Health Care Industry Market Research and Competitive Analysis 2010 | 730 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Plunkett's Health Care Technologies Overview 2010 (Summary) | 80 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Health Care Industry Trends, Statistics & Analysis 2010 (Summary) | 98 |
$199 |
0.16% Nasdaq 0.00%
Research Reports
